



Advances in Marine Chitin and Chitosan II, 2017

Guest Editors:

Prof. Dr. David Harding

Institute of Fundamental
Sciences, Massey University,
Private Bag 11 222, Palmerston
North, 4442, New Zealand

Dr. Hitoshi Sashiwa

Kaneka Co., Ltd, 5-1-1 Torikai-
Nishi, Settsu, Osaka 566-0072,
Japan

Deadline for manuscript
submissions:

closed (31 January 2017)

Message from the Guest Editors

Dear Colleagues,

As a result of our call in 2014 for submissions to a Special Issue, *Advances in Marine Chitin and Chitosan* in *Marine Drugs*, we are now pleased to tell you that this issue has been published. Twenty high class papers were included in this issue, which we now plan to publish as a book. In addition we now seek to publish a further Special Issue, *Advances in Marine Chitin and Chitosan II, 2017*, in *Marine Drugs*. As before, we plan to produce a strong, very exciting issue that will encompass breakthroughs in high value, scientific and industrial chitin and chitosan research. Despite significant advances in chitin and chitosan research since the 1970s, current overviews in recent publications involving chitin and chitosan research advances need reporting.

We look forward very much to your input.

Dr. Hitoshi Sashiwa,
Prof. Dr. David Harding,
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmacology, Toxicology and Pharmaceutics (miscellaneous)*)

Contact Us

Marine Drugs Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
X@Marine_Drugs